BACKGROUND: The "Walking Forward" program is a scientific collaborative program between Rapid City Regional Hospital, the University of Wisconsin, the Mayo Clinic, and partnerships with the American Indian community in western South Dakota-3 reservations and 1 urban population. The purpose is to increase participation of health disparities populations on National Cancer Institute clinical trials as part of the Cancer Disparities Research Partnership program. Clinical practice suggests that Native American cancer patients present with more advanced stages of cancer and hence have lower cure rates and higher treatment-related morbidities. It is hypothesized that a conventional course of cancer treatment lasting 6 to 8 weeks may be a barrier. METHODS: Innovative clinical trials have been developed to shorten the course of treatment. A molecular predisposition to treatment side effects is also explored. These clinical endeavors will be performed in conjunction with a patient navigator research program. RESULTS AND CONCLUSIONS: Research metrics include analysis of process, clinical trials participation, treatment outcome, and assessment of access to cancer care at an early stage of disease.
BACKGROUND: The "Walking Forward" program is a scientific collaborative program between Rapid City Regional Hospital, the University of Wisconsin, the Mayo Clinic, and partnerships with the American Indian community in western South Dakota-3 reservations and 1 urban population. The purpose is to increase participation of health disparities populations on National Cancer Institute clinical trials as part of the Cancer Disparities Research Partnership program. Clinical practice suggests that Native American cancerpatients present with more advanced stages of cancer and hence have lower cure rates and higher treatment-related morbidities. It is hypothesized that a conventional course of cancer treatment lasting 6 to 8 weeks may be a barrier. METHODS: Innovative clinical trials have been developed to shorten the course of treatment. A molecular predisposition to treatment side effects is also explored. These clinical endeavors will be performed in conjunction with a patient navigator research program. RESULTS AND CONCLUSIONS: Research metrics include analysis of process, clinical trials participation, treatment outcome, and assessment of access to cancer care at an early stage of disease.
Authors: B Ashleigh Guadagnolo; Amy Boylan; Michele Sargent; David Koop; Deb Brunette; Shalini Kanekar; Vanessa Shortbull; Kevin Molloy; Daniel G Petereit Journal: Cancer Date: 2010-12-14 Impact factor: 6.860
Authors: B Ashleigh Guadagnolo; Daniel G Petereit; Petra Helbig; David Koop; Patricia Kussman; Emily Fox Dunn; Asha Patnaik Journal: Clin Trials Date: 2009-11-23 Impact factor: 2.486
Authors: Kristen J Wells; Tracy A Battaglia; Donald J Dudley; Roland Garcia; Amanda Greene; Elizabeth Calhoun; Jeanne S Mandelblatt; Electra D Paskett; Peter C Raich Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Daniel G Petereit; Kevin Molloy; Mary L Reiner; Petra Helbig; Kristin Cina; Raylene Miner; Caroline Spotted Tail; Catherine Rost; Patricia Conroy; Chester R Roberts Journal: Cancer Control Date: 2008-07 Impact factor: 3.302
Authors: B Ashleigh Guadagnolo; Kristin Cina; Petra Helbig; Kevin Molloy; Mary Reiner; E Francis Cook; Daniel G Petereit Journal: J Health Care Poor Underserved Date: 2009-02